Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

Pemetrexed and Erlotinib for Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Pemetrexed
Drug: Erlotinib

First Posted Date: 2016-03-30

Last Posted Date: 2020-01-13

Lead Sponsor: Yonsei University

Target Recruit Count: 50

Registration Number: NCT02723578

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Genetic Predictors of Benefit to Pembrolizumab

Phase 2

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Pembrolizumab
Drug: Carboplatin
Drug: Nab-paclitaxel
Drug: Pemetrexed

First Posted Date: 2016-03-16

Last Posted Date: 2023-07-24

Lead Sponsor: Columbia University

Target Recruit Count: 19

Registration Number: NCT02710396

Locations: 🇺🇸
Columbia University, New York, New York, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Atezolizumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Pemetrexed

First Posted Date: 2016-01-15

Last Posted Date: 2023-11-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 578

Registration Number: NCT02657434

Locations: 🇺🇸
Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States
🇺🇸
Fort Wayne Med Oncology & Hematology Inc, Fort Wayne, Indiana, United States
🇺🇸
Oncology Consultants PA, Houston, Texas, United States

and more 180 locations

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

Phase 3

Terminated

Conditions: Non Small Cell Lung Cancer

Interventions: Biological: OSE2101
Drug: Docetaxel
Drug: Pemetrexed

First Posted Date: 2016-01-13

Last Posted Date: 2024-02-02

Lead Sponsor: OSE Immunotherapeutics

Target Recruit Count: 219

Registration Number: NCT02654587

Locations: 🇮🇱
Soroka University Medical Center, Be'er Sheva, Israel
🇫🇷
Clinique Victor Hugo, Le Mans, France
🇫🇷
Hôpital d'Instruction des Armées Bégin, Saint Mandé, France

and more 74 locations

Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors

Phase 1

Completed

Conditions: Medical Oncology

Interventions: Drug: BAY 94-9343
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2015-12-24

Last Posted Date: 2019-11-07

Lead Sponsor: Bayer

Target Recruit Count: 36

Registration Number: NCT02639091

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: Amivantamab
Drug: Lazertinib
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2015-11-20

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 751

Registration Number: NCT02609776

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Phase 3

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Alectinib
Drug: Docetaxel
Drug: Pemetrexed

First Posted Date: 2015-11-13

Last Posted Date: 2019-10-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 119

Registration Number: NCT02604342

Locations: 🇮🇹
Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Perugia, Umbria, Italy
🇵🇱
Medical University of Gdansk, Gdansk, Poland
🇮🇹
Azienda Ospedaliera San Camillo Forlanini; U.O.C. Pneumologia Ad Indirizzo Oncologico 1, Roma, Lazio, Italy

and more 51 locations

the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer(NSCLC)

Interventions: Drug: JinFuKang
Drug: Cisplatin
Drug: Pemetrexed

First Posted Date: 2015-11-11

Last Posted Date: 2019-09-20

Lead Sponsor: Shanghai University of Traditional Chinese Medicine

Target Recruit Count: 218

Registration Number: NCT02603003

Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE)

Phase 2

Terminated

Conditions: Non-small-cell Lung Cancer With Somatic EGFR Mutations

Interventions: Drug: Afatinib
Drug: Pemetrexed

First Posted Date: 2015-11-04

Last Posted Date: 2019-04-19

Lead Sponsor: Universität Duisburg-Essen

Target Recruit Count: 4

Registration Number: NCT02595840

Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: MK-3475
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pemetrexed

First Posted Date: 2015-10-29

Last Posted Date: 2022-12-28

Lead Sponsor: Alliance Foundation Trials, LLC.

Target Recruit Count: 91

Registration Number: NCT02591615

Locations: 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸
Medical Oncology & Hematology Associates, Des Moines, Iowa, United States
🇺🇸
NorthShore University HealthSystem, Evanston, Illinois, United States

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy